Hyperion DeFi (NASDAQ:HYPD) Stock Price Expected to Rise, Chardan Capital Analyst Says

Key Points

• Chardan Capital raised Hyperion DeFi’s price target to $8.45 from $7.30 and maintained a “buy” rating, implying approximately 133% upside from the stock’s $3.63 price.
• Analyst sentiment remains mixed: two analysts rate the stock a Buy and two rate it a Sell, resulting in a consensus “Hold” rating and an average price target of $7.77.
• Hyperion DeFi reported $0.92 in quarterly EPS on $0.36 million in revenue, while institutional investors own 25.84% of the company’s shares.

Hyperion DeFi (NASDAQ:HYPD - Get Free Report) had its target price raised by equities research analysts at Chardan Capital from $7.30 to $8.45 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. Chardan Capital's target price points to a potential upside of 132.97% from the stock's current price.

Several other analysts also recently commented on the stock. Weiss Ratings upgraded shares of Hyperion DeFi from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday, September 1st. Zacks Research lowered Hyperion DeFi from a "hold" rating to a "strong sell" rating in a research note on Wednesday, August 12th. Finally, Cantor Fitzgerald raised their price target on Hyperion DeFi from $6.60 to $7.10 and gave the company an "overweight" rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Hyperion DeFi currently has an average rating of "Hold" and a consensus price target of $7.77.

Hyperion DeFi Stock Performance

Shares of HYPD stock traded up $0.33 during trading hours on Tuesday, reaching $3.63. 884,686 shares of the company traded hands, compared to its average volume of 460,093. Hyperion DeFi has a 12-month low of $2.34 and a 12-month high of $15.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.34 and a quick ratio of 2.34. The company has a market cap of $56.36 million, a P/E ratio of -0.54 and a beta of 2.53. The firm has a 50-day moving average price of $2.93 and a 200 day moving average price of $3.28.

Hyperion DeFi (NASDAQ:HYPD - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported $0.92 earnings per share (EPS) for the quarter. The company had revenue of $0.36 million during the quarter. Hyperion DeFi had a net margin of 416.56% and a negative return on equity of 11.62%. As a group, sell-side analysts predict that Hyperion DeFi will post 1.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HYPD. Investment House LLC bought a new position in Hyperion DeFi in the fourth quarter worth approximately $166,000. Jane Street Group LLC bought a new stake in shares of Hyperion DeFi in the 4th quarter valued at about $493,000. Renaissance Technologies LLC bought a new position in shares of Hyperion DeFi during the fourth quarter valued at approximately $663,000. Focus Partners Advisor Solutions LLC bought a new position in Hyperion DeFi in the fourth quarter worth approximately $221,000. Finally, Geode Capital Management LLC purchased a new stake in Hyperion DeFi during the fourth quarter worth $214,000. Hedge funds and other institutional investors own 25.84% of the company's stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.